SCHEMBL19781608

SCHEMBL19781608

CC(C)Oc1ccc(-c2ncc3ncn(-c4ccc(OC(C)C)cc4)c3n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.46
NT5E P21589 1/20 0.41
CYP11B2 P19099 1/20 0.40
MAPK6 Q16659 1/20 0.40
MAPT P10636 3/20 0.38
KMT2A Q03164 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
PTK2B Q14289 1/20 0.38
HTT P42858 2/20 0.38
MCHR1 Q99705 1/20 0.38
ATM Q13315 1/20 0.37
RPS6KA3 P51812 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
POLB P06746 1/20 0.37
CYP2D6 P10635 1/20 0.37
THRB P10828 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
MAOA P21397 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19781280 0.90 FGFR1 (0.39) FGFR1NT5ECYP11B2MAPK6MAPT
SCHEMBL21449952 0.85 GABRP (0.43) FGFR1NT5EMCHR1KDRKCNH2
SCHEMBL19781259 0.83 FGFR1 (0.47) FGFR1CYP11B2MAPK6MAPTKMT2A
SCHEMBL19781576 0.81 DYRK1A (0.50) FGFR1CYP11B2MAPTKMT2ANPSR1
SCHEMBL19781256 0.76 FGFR1 (0.48) FGFR1CYP11B2MAPK6MAPTKMT2A
SCHEMBL21449908 0.75 DYRK1A (0.55) FGFR1CYP11B2MAPTKMT2AATM
SCHEMBL19781537 0.74 KCNH2 (0.55) FGFR1CYP11B2MAPTKMT2ANPSR1
SCHEMBL19781531 0.72 DYRK1A (0.45) FGFR1CYP11B2MAPTHTTMCHR1
SCHEMBL19781511 0.72 FGFR1 (0.59) FGFR1CYP11B2MAPTHTTATM
SCHEMBL21449929 0.71 GABRP (0.45) FGFR1ATMKDRKCNH2DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
WO-2018013430-A2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S FGFR1 3928/4885NT5E 2850/4885CYP11B2 2387/4885
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus C9, C1R, C1S FGFR1 3928/4885NT5E 2850/4885CYP11B2 2387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.